Najat Khan

Insider · CEO and President · RXRX

Najat Khan files insider transactions with the SEC as a ceo and president of Recursion Pharmaceuticals. We hold 3 disclosed purchases and sales filed since 5 August 2024, 1 of them in the last 90 days.

Files forRXRX
Disclosed buys and sells3 in all, 1 in the last 90 days
Last disclosure10 September 2026

Positions held

1 post we hold — a term names its own dates; a run of filings only says when they filed

Filed 1 August 2024 — 8 September 2026CEO and President · Recursion Pharmaceuticals 27 Form 4 lines · source: SEC Form 4

Every transaction

27 transactions from SEC Form 4 — one row each, sort any column, open a row for the filing

Sort byOpen-market trades only27 of 27 shown


8 Sep 2026	10 Sep 2026SEC Form 4	2 d	sold on the open market	Recursion Pharmaceuticals	22,408 shares	down −7.0%	up +1.3%
17 Aug 2026	18 Aug 2026SEC Form 4	1 d	had shares withheld for taxnot a trade	Recursion Pharmaceuticals	80,498 shares	up +2.9%	up +3.6%
5 Jun 2026	5 Jun 2026SEC Form 4	0 d	sold on the open market	Recursion Pharmaceuticals	23,588 shares	down −3.5%	down −3.5%
15 May 2026	19 May 2026SEC Form 4	4 d	had shares withheld for taxnot a trade	Recursion Pharmaceuticals	62,701 shares	up +9.2%	up +12.3%
9 Mar 2026	11 Mar 2026SEC Form 4	2 d	sold on the open market	Recursion Pharmaceuticals	28,298 shares	down −8.8%	down −7.2%
9 Mar 2026	11 Mar 2026SEC Form 4	2 d	sold on the open market	Recursion Pharmaceuticals	28,298 shares	down −8.8%	down −7.2%
17 Feb 2026	19 Feb 2026SEC Form 4	2 d	had shares withheld for taxnot a trade	Recursion Pharmaceuticals	14,280 shares	down −7.5%	down −14.0%
17 Feb 2026	19 Feb 2026SEC Form 4	2 d	had shares withheld for taxnot a trade	Recursion Pharmaceuticals	14,280 shares	down −7.5%	down −14.0%
6 Feb 2026	10 Feb 2026SEC Form 4	4 d	was grantednot a trade	Recursion Pharmaceuticals	1,673,546 shares	down −19.6%	down −16.9%
6 Feb 2026	10 Feb 2026SEC Form 4	4 d	was grantednot a trade	Recursion Pharmaceuticals	30,346 shares	down −19.6%	down −16.9%
6 Feb 2026	10 Feb 2026SEC Form 4	4 d	had shares withheld for taxnot a trade	Recursion Pharmaceuticals	10,364 shares	down −19.6%	down −16.9%
6 Feb 2026	10 Feb 2026SEC Form 4	4 d	was grantednot a trade	Recursion Pharmaceuticals	1,673,546 shares	down −19.6%	down −16.9%
6 Feb 2026	10 Feb 2026SEC Form 4	4 d	was grantednot a trade	Recursion Pharmaceuticals	30,346 shares	down −19.6%	down −16.9%
6 Feb 2026	10 Feb 2026SEC Form 4	4 d	had shares withheld for taxnot a trade	Recursion Pharmaceuticals	10,364 shares	down −19.6%	down −16.9%
22 Dec 2025	29 Dec 2025SEC Form 4	7 d	sold on the open market	Recursion Pharmaceuticals	124,403 shares	down −27.3%	down −22.5%
17 Nov 2025	19 Nov 2025SEC Form 4	2 d	had shares withheld for taxnot a trade	Recursion Pharmaceuticals	17,584 shares	down −22.3%	down −20.6%
5 Nov 2025	6 Nov 2025SEC Form 4	1 d	was grantednot a trade	Recursion Pharmaceuticalsderivative	169,851 shares	down −35.5%	down −30.7%
5 Nov 2025	6 Nov 2025SEC Form 4	1 d	was grantednot a trade	Recursion Pharmaceuticals	84,925 shares	down −35.5%	down −30.7%
18 Aug 2025	19 Aug 2025SEC Form 4	1 d	sold on the open market	Recursion Pharmaceuticals	36,599 shares	down −42.0%	down −37.1%
15 Aug 2025	19 Aug 2025SEC Form 4	4 d	had shares withheld for taxnot a trade	Recursion Pharmaceuticals	3,789 shares	down −44.5%	down −37.1%
15 May 2025	19 May 2025SEC Form 4	4 d	had shares withheld for taxnot a trade	Recursion Pharmaceuticals	3,796 shares	down −24.7%	down −29.0%
3 Feb 2025	5 Feb 2025SEC Form 4	2 d	was grantednot a trade	Recursion Pharmaceuticalsderivative	420,226 shares	down −55.9%	down −59.6%
3 Feb 2025	5 Feb 2025SEC Form 4	2 d	was grantednot a trade	Recursion Pharmaceuticals	210,113 shares	down −55.9%	down −59.6%
3 Feb 2025	5 Feb 2025SEC Form 4	2 d	was grantednot a trade	Recursion Pharmaceuticals	8,049 shares	down −55.9%	down −59.6%
3 Feb 2025	5 Feb 2025SEC Form 4	2 d	had shares withheld for taxnot a trade	Recursion Pharmaceuticals	2,753 shares	down −55.9%	down −59.6%
1 Aug 2024	5 Aug 2024SEC Form 4	4 d	was grantednot a trade	Recursion Pharmaceuticalsderivative	993,944 shares	down −56.4%	down −52.7%
1 Aug 2024	5 Aug 2024SEC Form 4	4 d	was grantednot a trade	Recursion Pharmaceuticals	496,972 shares	down −56.4%	down −52.7%

Both percentages are the stock’s move, not Najat Khan’s return: a disclosure gives a band, never an amount, so nobody can say how much was bought or what it made. They run to the last close we hold — 11 Sep 2026, except where a name has since delisted, when the row names its own last session. We publish no close, no volume and no dollar figure behind them. 27 of the 27 rows shown carry a percentage; the rest are dashes with the reason on the row.

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.

Some filings reach us as photographs of paper rather than as a form we can read as text. Those are shown here only once they have been read and checked, so this page can hold fewer lines than the filings behind it contain. The link on every row opens the original document, which is always the full record.